A single centre, randomised controlled, open label study of rituximab as induction therapy in kidney transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN07963178

Enrollment

120

Registered

2005-05-10

Start date

2006-04-01

Completion date

Unknown

Last updated

2017-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunosuppression following renal transplantation Surgery Kidney transplant

Interventions

Comparision of rituximab with daclizumab as induction immunosuppression following renal transplantation Added 01/02/2010: The trial was stopped prematurely due to an excess of acute rejection in the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing renal transplantation

Exclusion criteria

Exclusion criteria: Age under 18 years

Design outcomes

Primary

Measure	Time frame
1. Acute rejection incidence 2. Acute rejection severity - Banff scale 3. Incidence of steroid resistant rejection, defined as the need for ATG therapy	—

Secondary

Measure	Time frame
1. Patient survival 2. Graft survival 3. Graft function ? estimated glomerular filtration rate (GFR) 4. Incidence of infection ? culture positive infections 5. Incidence of C4d+ endothelial staining together with infiltrate on renal biopsy 6. Incidence of anti-donor HLA-specific antibody in post transplant sera	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026